Latest Prilenia Therapeutics News & Updates

See the latest news and media coverage for Prilenia Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Prilenia Therapeutics

Clinical-stage biotech developing neurodegenerative disease treatments

prilenia.com
Headquarters
Boston, United States
Founded year
2018
Company type
Private company
Number of employees
10–60

Latest news about Prilenia Therapeutics

Company announcements

  • Prilenia Therapeutics

    Prilenia appoints Elisabeth Leiderman as CFO

    She brings over 20 years of finance and biotech experience, including fundraising and strategic transactions. The appointment supports Phase 3 studies for HD and ALS.

  • Prilenia Therapeutics

    Prilenia announces first enrollment in PREVAiLS Phase 3 ALS study

    The 500-participant trial evaluates pridopidine's efficacy in slowing progression for early, rapidly progressive ALS patients across 13 countries.

  • Prilenia Therapeutics

    Prilenia Therapeutics presents Phase 3 PREVAiLS study design

    Dr. Angela Genge presented at the 2026 Muscular Dystrophy Association Conference. The global study of pridopidine in early ALS enrolls soon in Canada.

  • Prilenia Therapeutics

    Prilenia starts Phase 3 trials for ALS and HD

    Women comprise 65% of the team and 55% of senior management, with four of five study leaders being women. Prilenia celebrates Women and Girls in Science daily.

Unlock all announcements with a

Media coverage

Unlock all articles with a

Never miss news about Prilenia Therapeutics

Track Prilenia Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Prilenia Therapeutics competitors & trending companies

Browse news for competitors to Prilenia Therapeutics and other trending companies.